Nuwellis (NUWE) stock
NUWE · Nuwellis Inc. · NASDAQ
- Market cap
- $1.8M
- Shares out
- 541K
Why is NUWE stock moving today?
Live discussion will feature study investigators examining clinical findings, treatment outcomes, and the role of ultrafiltration in pediatric fluid management MINNEAPOLIS, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will host a live educational webinar, "ULTRA-Peds Results Analysis and Discussion," on December 1, 2026, at 1:00 p.m. Eastern Time. The event will feature a panel of lead and contributing authors of the multicenter study titled "Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry," whi
All NUWE newsWhen does Nuwellis report earnings?
Nuwellis last reported on Nov 12, 2026, the date it announced on Nov 4, 2026. Before that it reported on May 12, 2026 and Mar 10, 2026.
NUWE earnings historyFinancial highlights
Full financials- Revenue, TTM
- $9.01M
- Revenue growth
- +10.3%
- Net income, TTM
- -$13.76M
- Net margin
- -152.8%
- Free cash flow, TTM
- -$12.38M
- Cash
- $8.29M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRNuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric PatientsLive discussion will feature study investigators examining clinical findings, treatment outcomes, and the role of ultrafiltration in pediatric fluid management MINNEAPOLIS, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will host a live educational webinar, "ULTRA-Peds Results Analysis and Discussion," on December 1, 2026, at 1:00 p.m. Eastern Time. The event will feature a panel of lead and contributing authors of the multicenter study titled "Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry," whi
- SECNuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 10-Q filed by Nuwellis Inc.10-Q - Nuwellis, Inc. (0001506492) (Filer)
- SECNuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating LossConsole unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue Advanced growth strategy with 510(k) submission for Aquadex label expansion and two product portfolio-expanding agreements leveraging existing sales force Company to conduct conference call beginning at 9:00 a.m. Eastern time today MINNEAPOLIS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026. Third Quarter 2026 Finan
- PRNuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small ChildrenMINNEAPOLIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has secured exclusive U.S. distribution rights for the pediatric Zorro-Flow® urine collection system. Under the agreement, Nuwellis will serve as the commercial arm for the product in the U.S., further expanding its presence across neonatal and pediatric critical care. Zorro-Flow is a non-invasive urine collection system designed for neonates and small children, offering clinicians an easy-to-use, safe, effective non-invasive alternative to traditional methods that do not work well. "A
- PRNuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and AboveMINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of its Aquadex SmartFlow® System to include pediatric patients weighing 5 kg and above. The system is currently cleared for use in patients weighing 20 kg and above. "This submission represents an important step in our strategy to expand access to Aquadex therapy for some of the smallest and most vulnerable patients," said Mike McCormick, President and Chief Exec
- PRNuwellis to Report Third Quarter 2026 Financial Results on November 12MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 12, 2026, and will host a conference call beginning at 9:00 a.m. Eastern time. Conference Call & Webcast Information Date: Thursday, November 12th Time: 9:00 a.m. Eastern timeDomestic Dial-in: (833) 309-3473International Dial-in: (785) 838-9251 Conference ID: NUWEQ3Live and Replay Webcast: https://ir.nuwellis.com or available here About Nuwelli
- PRNuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric NephrologyMINNEAPOLIS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the publication of results from a multicenter study titled "Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry" in Pediatric Nephrology. It provides important clinical evidence supporting the use of the Company's Aquadex SmartFlow® System ultrafiltration technology in pediatric patients, including infants and children weighing less than 10 kg. The publication examining the outcomes and implications was authored by Michelle C. Starr, M.D., MPH; Stuart L. G
- SECSEC Form 8-K filed by Nuwellis Inc.8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT SystemMINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform. "Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for them," sa
- PRNuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical ConferencesMINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow® system in providing precise, controlled fluid removal for patients who require individualized fluid management. "Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a common and
- PRNuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue OpportunityMINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow® system, with 31 consoles sold year-to-date in 2026. The Company's year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026. "Selling 31 consoles at this point in the
- PRNuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory AffairsMINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of medical device quality and regulatory experience, with a proven track record leading quality systems, regulatory activities, audits and product development initiatives. His appointment strengthens Nuwellis' quality and regulatory capabilities as the Company continues to invest in the expertise needed to advance product development, commercialization and initiatives across the cardiorenal c
- PRNuwellis Advances Financial Efficiency Strategy with Improved Gross MarginsMINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure. This strategy continues to advance alongside a strengthened cash position, extending the Company’s operating runway into the third quarter of 2027. "Over the past year, we have made meaningful progress building a more efficient and scalable operating model while continuing to grow revenues at a d
- SECSEC Form EFFECT filed by Nuwellis Inc.EFFECT - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 424B3 filed by Nuwellis Inc.424B3 - Nuwellis, Inc. (0001506492) (Filer)
- SECNuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility MedicalMINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility Medical, Inc, a cardiac medical technology company, today announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp® device. "AtriAmp is an excellent strategic fit with Nuwellis' growing pediatric and critical care portfolio, serving many of the same hospitals, physicians and care teams that our commercial organization supports today," said Mike McCormick, Nuwellis President and Chief Executive Officer. "This staged agreement is anothe
- SECSEC Form S-3 filed by Nuwellis Inc.S-3 - Nuwellis, Inc. (0001506492) (Filer)
- SECNuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 10-Q filed by Nuwellis Inc.10-Q - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross MarginRecent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026. Second Quarter Results and Recent Highlights: Net sales were $2.0 million in the second quarter, a 14% increase compared with the prior-year period; U.S. revenue increased 17%Net sales for the first six months of 2026 were $4.4 million, a 20% increase compared with the prior-year
- PRNuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User InterfaceMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced a digital transformation program designed to position the Aquadex SmartFlow® System as a connected extracorporeal therapy platform for the modern intensive care environment. The program includes integration through Philips Capsule™ medical device interoperability technology and development of a next-generation tablet-based user interface. Together, these enhancements are expected to improve clinical workflow, strengthen interoperability with hospital information systems, and establish the digita
- PRNuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D EngineerMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch. As Principal R&D Engineer, Brady joins Nuwellis’ research and development team to advance its existing and new product development programs. "Dale's experience developing inno
NUWE rankings
- Other9(47%)
- SEC Filings7(37%)
- Earnings2(11%)
- Leadership1(5%)
Nuwellis Inc. (NUWE) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for NUWE, including 4 SEC filings, 4 press releases and news items and 2 earnings updates. The most recent was published Nov 19, 2026.
NUWE FAQ
9 questionsWhat does Nuwellis Inc. do?
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria...What is NUWE revenue?
Nuwellis Inc. (NUWE) reported $9.01M of revenue for the twelve months ended Sep 30, 2026. That is up 10.3% from the year before. Revenue for fiscal 2025 was $8.27M.Is NUWE profitable?
No. Nuwellis Inc. reported a net loss of $13.76M for the twelve months ended Sep 30, 2026.How much cash and debt does NUWE have?
Nuwellis Inc. reported $8.29M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NUWE stock trade?
Nuwellis Inc. (NUWE) is listed on NASDAQ.What sector and industry is NUWE in?
Nuwellis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about NUWE?
Nuwellis Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $17.00 price target on 2024-07-29. Recent price targets cluster around $17.00.What companies are similar to NUWE?
Notable peers in the same industry include BAX (Baxter International Inc.), MDT (Medtronic plc.), FMS (Fresenius Medical Care AG), OM (Outset Medical Inc.). Compare NUWE side-by-side with any of them on Quantisnow.How can I track NUWE on Quantisnow?
Quantisnow aggregates Nuwellis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUWE to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change